O
One Biosciences
Biotech & Life Sciences · Paris, France · Founded 2020
Operating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases MoreLess
One Biosciences operates in the biotechnology sector, focusing on the development of RNA-based therapies aimed at precision medicine. The company leverages advanced RNA technologies to create personalized healthcare solutions, targeting specific genetic profiles to treat various diseases. One Biosciences primarily serves healthcare providers, pharmaceutical companies, and research institutions. The company operates in the global biotechnology market, which is characterized by rapid innovation and high growth potential. Its business model revolves around research and development, clinical trials, and eventual commercialization of its RNA-based therapies. Revenue is generated through partnerships, licensing agreements, and sales of proprietary treatments. The company is led by a team of experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and finance, ensuring a strong foundation for growth and innovation.
Keywords: RNA-based therapies, precision medicine, personalized healthcare, biotechnology, genetic profiles, clinical trials, pharmaceutical partnerships, healthcare innovation, advanced RNA technologies, global market.
Company overview
One Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Paris, France
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 91.6
Valuation & funding
One Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jun 2026 | $0 | — | Capscion · Incuballiance Paris-Saclay | ↗ |
| SERIES A✓Equity / VC | Jul 2025 | $17M | $66M | Galion.exe · Adamed Technology · Redmile Group · Polytechnique Ventures | ↗ |
| SERIES A✓Equity / VC | Sep 2022 | $7.7M | $31M | HOME BIOSCIENCES · Institut Curie | — |
| EARLY VCEquity / VC | Oct 2020 | $0 | — | Undisclosed | — |
| SPINOUT✓Other financing | Sep 2020 | $0 | — | CNRS Innovation · French National Centre for Scientific Research - CNRS · PSL University · Institut Curie | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 43 |
| 2025 | 36 |
| 2024 | 17 |
| 2023 | 15 |
| 2022 | 10 |
Growth signals
One Biosciences website traffic
Latest recorded traffic for One Biosciences is 620 monthly website visits, up 29.2% over the last three months. One Biosciences's team grew 19.4% over the past year.
Comparisons
One Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
One Biosciences's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where One Biosciences has talent and traffic
team presence
In the news
Latest news about One Biosciences
Recent press, funding announcements, and product moves mentioning One Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about One Biosciences
An AI-synthesized read of the highest-engagement posts about One Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See One Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.